LONDON – Another divide over patents is opening up between the U.S. and Europe as biomarkers are coming into more widespread use. Public sector genetic testing laboratories in Europe are ignoring intellectual property (IP) rights both because they do not think they are enforceable and because of a belief that such patents are not justified.